| Literature DB >> 25861438 |
Zahra Seifi1, Ali Zarei Mahmoudabadi2, Majid Zarrin1.
Abstract
BACKGROUND: Extracellular phospholipase, proteinase, and coagulase are accounted as the major virulence factors in Candida albicans. Several reports showed that the incidence of resistance to fluconazole has risen during last two decades.Entities:
Keywords: Candida albicans; Coagulase; Fluconazole; Phospholipase; Vulvovaginal Candidiasis
Year: 2015 PMID: 25861438 PMCID: PMC4386072 DOI: 10.5812/jjm.20162
Source DB: PubMed Journal: Jundishapur J Microbiol ISSN: 2008-3645 Impact factor: 0.747
Figure 1.Phospholipase Precipitation Zone Around C. albicans
Figure 2.Proteinase Clear Zone Around C. albicans (Stained With Amido Black)
Frequency of Recovered Candida Species From Patients With Candida Vaginitis and Healthy Individuals[a]
| Healthy Individuals | Patients With | |
|---|---|---|
|
| 19 (45.2) | 32 (48.5) |
|
| 11 (26.2) | 15 (22.7) |
|
| 2 (4.8) | 11 (16.7) |
|
| 1 (2.4) | 1 (1.5) |
|
| 4 (9.5) | 0 (0.0) |
|
| 0 (0.0) | 1 (1.5) |
|
| 1 (2.4) | 3 (4.5) |
|
| 0 (0.0) | 1 (1.5) |
| 4 (9.5) | 2 (3.1) |
aData are presented as No. (%).
Phospholipase Production in 108 Isolates of Candida Species From Patients With Vaginitis and Healthy Individuals[a]
| Healthy Individuals | Patients With Vaginitis | |||
|---|---|---|---|---|
| Negative | Positive | Negative | Positive | |
|
| 2 (4.8) | 17 (40.5) | 5 (6.1) | 28 (42.4) |
|
| 0 (0.0) | 2 (4.8) | 1 (1.5) | 10 (15.2) |
|
| 9 (21.4) | 2 (4.8) | 12 (18.2) | 3 (4.5) |
|
| 1 (2.4) | 0 (0.0) | 0 (0.0) | 1 (1.5) |
|
| 9 (21.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
|
| 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.5) |
|
| 1 (2.4) | 0 (0.0) | 3 (4.5) | 0 (0.0) |
|
| 0 (0.0) | 0 (0.0) | 1 (1.5) | 0 (0.0) |
| 2 (4.8) | 2 (4.8) | 1 (1.5) | 1 (1.5) | |
aData are presented as No. (%).
Proteinase Production in 108 Isolates of Candida Species From Patients With Vaginitis and Healthy Individuals[a]
| Healthy Individuals | Patients With Vaginitis | |||
|---|---|---|---|---|
| Negative | Positive | Negative | Positive | |
|
| 7 (16.7) | 12 (28.6) | 8 (12.1) | 24 (36.4) |
|
| 1 (2.4) | 1 (2.4) | 4 (6.1) | 7 (10.6) |
|
| 7 (16.7) | 4 (9.5) | 3 (4.5) | 12 (8.2) |
|
| 0 (0.0) | 1 (2.4) | 1 (1.5) | 0 (0.0) |
|
| 0 (0.0) | 4 (9.5) | 0 (0.0) | 0 (0.0) |
|
| 0 (0.0) | 0 (0.0) | 1 (1.5) | 0 (0.0) |
|
| 0 (0.0) | 1 (2.4) | 0 (0.0) | 3 (4.5) |
|
| 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.5) |
| 1 (2.4) | 3 (7.1) | 0 (0.0) | 2 (3) | |
aData are presented as No. (%).
Sensitivity to Fluconazole Among 66 Isolates Recovered From Patients[a]
| Resistant | Dose Dependent | Sensitive | |
|---|---|---|---|
|
| 13 (19.7) | 4 (6.1) | 15 (22.7) |
|
| 6 (9.1) | 1 (1.5) | 4 (6.1) |
|
| 3 (4.5) | 2 (3.1) | 10 (15.2) |
|
| 0 (0.0) | 1 (1.5) | 0 (0.0) |
|
| 0 (0.0) | 0 (0.0) | 1 (1.5) |
|
| 0 (0.0) | 0 (0.0) | 3 (4.5) |
|
| 0 (0.0) | 0 (0.0) | 1 (1.5) |
| 1 (1.5) | 0 (0.0) | 1 (1.5) |
aData are presented as No. (%).